BIODESIX INC

Listed Company

BDSXCIK 0001439725NasdaqNon-AcceleratedSmaller ReportingServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$88.50M

Net Income

$-35.27M

Total Assets

$87.48M

Equity

$-2.46M

Shares Out

10.11M

Op. Cash Flow

$-23.27M

BDSX$20.20+6407.73% · past yearDBEQ Basic

Daily closing prices

Business

Biodesix is a diagnostic solutions company offering blood-based tests for lung disease diagnosis, treatment guidance, and monitoring. The company provides five commercial lung diagnostic tests addressing nodule risk assessment and non-small cell lung cancer treatment decisions, along with development services for biopharmaceutical and life sciences customers. Biodesix operates two clinical laboratories in Colorado and Kansas, markets primarily to pulmonologists and primary care networks in the United States, and generates revenue from diagnostic testing services and biopharmaceutical development contracts.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	88	71	49	38	55
Direct costs and expenses	17	16	13	14	31
Research and development	12	10	10	13	13
Sales, marketing, general and administrative	88	80	67	61	51
Impairment loss on intangible assets	107,000	238,000	44,000	81,000	—
Total operating expenses	116	106	90	89	95
Loss from operations	−28	−34	−41	−51	−41
Interest expense	−8	−8	−10	—	—
Loss on extinguishment of liabilities	—	−248,000	—	−7	2
Change in fair value of warrant liability, net	−280,000	—	−1	84,000	—
Other income , net	604,000	73,000	6,000	109,000	9,000
Total other expense	−7	−8	−11	—	—
Net loss	−35	−43	−52	−65	−43
Net loss per share, basic	−4.67	−6.64	−0.64	−1.55	−1.58
Net loss per share, diluted	−4.67	−6.64	−0.64	−1.55	−1.58
Weighted-average shares outstanding, basic	8	6	82	42	27
Weighted-average shares outstanding, diluted	8	6	82	42	27

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	19	26	26	43	33
Accounts receivable, net of allowance for credit losses of $62 and $481	9	9	8	5	4
Other current assets	4	5	6	5	7
Total current assets	33	39	40	53	44
Property and equipment, net	25	28	28	6	4
Intangible assets, net	4	6	8	10	12
Operating lease right-of-use assets	3	2	2	3	1
Goodwill	15	15	15	15	15
Other long-term assets	8	7	7	6	2
Total non-current assets	55	58	59	40	32
Total assets	87	97	99	93	76
Accounts payable	3	2	3	2	2
Accrued liabilities	11	10	8	8	8
Deferred revenue	1	700,000	300,000	1	2
Current portion of operating lease liabilities	1	719,000	252,000	2	—
Current portion of notes payable	6,000	21,000	51,000	49,000	19,000
Other current liabilities	992,000	641,000	293,000	41,000	—
Total current liabilities	17	14	33	23	29
Long-term notes payable, net of current portion	47	36	35	25	10
Long-term operating lease liabilities	24	25	25	5	—
Other long-term liabilities	1	815,000	712,000	558,000	1
Total non-current liabilities	73	62	61	49	27
Total liabilities	90	76	95	72	56
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2025 and 2024) issued and outstanding	—	—	—	—	—
Common stock, $0.001 par value, 200,000,000 authorized; 8,253,053 (2025) and 7,274,578 (2024) shares issued and outstanding	8,000	7,000	96,000	78,000	31,000
Additional paid-in capital	495	483	424	388	322
Accumulated deficit	−498	−462	−420	−367	−302
Total stockholders' (deficit) equity	−2	21	5	21	20
Total liabilities and stockholders' (deficit) equity	87	97	99	93	76

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−35	−43	−52	−65	−43
Depreciation and amortization	6	6	3	4	3
Accretion of lease right-of-use assets	−69,000	−317,000	—	—	—
Share-based compensation expense	4	7	5	6	5
Provision for credit losses	180,000	887,000	497,000	—	—
Accrued interest, amortization of debt issuance costs and other	1	2	5	5	3
Inventory excess and obsolescence	49,000	22,000	200,000	900,000	0
Accounts receivable	−531,000	−2	−5	−2	11
Other current assets	−258,000	716,000	905,000	1	1
Other long-term assets	−121,000	68,000	33,000	−4	—
Accounts payable and other accrued liabilities	2	2	513,000	−773,000	−7
Deferred revenue	174,000	248,000	−755,000	−1	−2
Contingent consideration	—	−23	−2	—	—
Current and long-term operating lease liabilities	−789,000	715,000	−503,000	−937,000	—
Net cash, cash equivalents, and restricted cash used in operating activities	−23	−49	−23	−45	−28
Purchase of property and equipment	−259,000	−3	−23	−3	−2
Patent costs and intangible asset acquisition, net	−144,000	−210,000	−143,000	−236,000	−306,000
Net cash, cash equivalents, and restricted cash used in investing activities	−403,000	−3	−23	−4	−3
Proceeds from the issuance of common stock	7	56	28	60	16
Proceeds from issuance of common stock under employee stock purchase plan	497,000	625,000	643,000	355,000	328,000
Proceeds from exercise of stock options	—	25,000	91,000	269,000	769,000
Proceeds from term loan and notes payable	10	—	10	45	30
Repayment of term loan and notes payable	−21,000	−51,000	−49,000	−29	−45
Payment of debt issuance costs	−30,000	−44,000	−833,000	−4	−164,000
Equity financing costs	−532,000	−4	−80,000	−3	—
Other	−817,000	−445,000	−188,000	−33,000	—
Net cash, cash equivalents, and restricted cash provided by financing activities	16	52	29	59	1
Net decrease in cash, cash equivalents, and restricted cash	−7	−39,000	−17	10	−30
Equity financing costs included in accounts payable and other accrued liabilities	7,000	—	43,000	160,000	—
Operating lease right-of-use asset obtained in exchange for lease liabilities	644,000	583,000	797,000	4	—
Finance lease right-of-use assets obtained in exchange for lease liabilities	1	999,000	773,000	123,000	—
Cash paid for interest	6	7	4	1	2
Change in fair value of Perceptive Warrants	227,000	—	—	—	—
Purchases of property & equipment included in accounts payable and accrued liabilities	27,000	—	793,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is BIODESIX INC's CIK number?

BIODESIX INC's SEC CIK number is 0001439725 (1439725). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find BIODESIX INC's SEC filings?

All of BIODESIX INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did BIODESIX INC last report earnings?

BIODESIX INC (BDSX) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-203936). This is BIODESIX INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is BIODESIX INC's most recent earnings 8-K?

BIODESIX INC's latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001193125-26-203936. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View BIODESIX INC's latest earnings 8-K →
Look up any company's CIK number →